Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 394

1.

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA.

Blood. 2010 Apr 29;115(17):3520-30. doi: 10.1182/blood-2009-09-246124. Epub 2010 Mar 2.

2.

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS.

Mol Cancer Ther. 2010 Feb;9(2):489-98. doi: 10.1158/1535-7163.MCT-09-0628. Epub 2010 Feb 2.

3.

Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.

Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA.

J Immunol. 2000 Apr 1;164(7):3596-9.

4.

Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase.

Funeshima N, Fujino M, Kitazawa Y, Hara Y, Hara Y, Hayakawa K, Okuyama T, Kimura H, Li XK.

J Gene Med. 2005 May;7(5):565-75.

PMID:
15543532
5.
6.

Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.

Schmidt SK, Müller A, Heseler K, Woite C, Spekker K, MacKenzie CR, Däubener W.

Eur J Immunol. 2009 Oct;39(10):2755-64. doi: 10.1002/eji.200939535.

7.

A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.

Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD.

Clin Cancer Res. 2009 Jan 15;15(2):641-9. doi: 10.1158/1078-0432.CCR-08-1988.

8.

p-Coumaric acid inhibits indoleamine 2, 3-dioxygenase expression in murine dendritic cells.

Kim SI, Jeong YI, Jung ID, Lee JS, Lee CM, Yoon MS, Seong EY, Kim JI, Lee JD, Park YM.

Int Immunopharmacol. 2007 Jun;7(6):805-15. Epub 2007 Feb 27.

PMID:
17466914
9.

CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.

von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS, Fiore F, Roth U, Beyer M, Debey S, Wickenhauser C, Hanisch FG, Schultze JL.

Blood. 2006 Jul 1;108(1):228-37. Epub 2006 Mar 7.

10.

Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F.

Clin Cancer Res. 2008 Nov 15;14(22):7251-9. doi: 10.1158/1078-0432.CCR-08-0991.

11.

Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.

Yuasa HJ, Ball HJ, Ho YF, Austin CJ, Whittington CM, Belov K, Maghzal GJ, Jermiin LS, Hunt NH.

Comp Biochem Physiol B Biochem Mol Biol. 2009 Jun;153(2):137-44.

PMID:
19402226
12.

A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation.

Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL.

Int Immunol. 2005 Jul;17(7):909-19. Epub 2005 Jun 20.

PMID:
15967784
13.

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.

Löb S, Königsrainer A, Zieker D, Brücher BL, Rammensee HG, Opelz G, Terness P.

Cancer Immunol Immunother. 2009 Jan;58(1):153-7. doi: 10.1007/s00262-008-0513-6. Epub 2008 Apr 17.

PMID:
18418598
14.

Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.

Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S.

J Exp Ther Oncol. 2003 Nov-Dec;3(6):336-45.

PMID:
14678522
15.

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.

Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH.

Int Immunol. 2004 Oct;16(10):1391-401. Epub 2004 Sep 6.

PMID:
15351783
16.

Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction.

Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, Chieppa M, Rescigno M.

Gut. 2010 May;59(5):595-604. doi: 10.1136/gut.2009.185108.

PMID:
20427394
17.

Blockade of IDO inhibits nasal tolerance induction.

van der Marel AP, Samsom JN, Greuter M, van Berkel LA, O'Toole T, Kraal G, Mebius RE.

J Immunol. 2007 Jul 15;179(2):894-900.

18.

Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.

Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7641-6. doi: 10.1016/j.bmcl.2012.10.010. Epub 2012 Oct 11.

PMID:
23122865
19.

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.

Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P.

Blood. 2008 Feb 15;111(4):2152-4. Epub 2007 Nov 28.

20.

Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2.

Austin CJ, Mailu BM, Maghzal GJ, Sanchez-Perez A, Rahlfs S, Zocher K, Yuasa HJ, Arthur JW, Becker K, Stocker R, Hunt NH, Ball HJ.

Amino Acids. 2010 Jul;39(2):565-78. doi: 10.1007/s00726-010-0475-9. Epub 2010 Feb 7.

PMID:
20140689

Supplemental Content

Support Center